Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Targeted therapies inhibiting the MAPK pathway have shown initial success in treating metastatic melanoma.
• However, most patients eventually experience disease progression due to acquired therapy resistance.

Purpose of the Study:

• To review current concepts of resistance to MAPK pathway inhibitors in melanoma.
• To highlight the roles of inter- and intra-individual, and intratumor heterogeneity in resistance development.

Main Methods:

• This review synthesizes existing research on melanoma resistance mechanisms.
• Focuses on genetic mutations and phenotypic adaptations driving resistance to MAPK inhibitors.

Main Results:

• Melanoma cell plasticity facilitates clonal evolution and the emergence of resistant phenotypes.
• Resistance involves genetic alterations (e.g., MAPK, PI3K/AKT/PTEN pathways) and metabolic/functional adaptations.
• Melanoma cells dynamically shift states (metabolic, cell cycle, differentiation) to overcome drug stress.

Conclusions:

• Melanoma's adaptability presents a significant challenge for MAPK inhibitor therapy.
• Further research into heterogeneity and plasticity is crucial for developing more effective melanoma treatments.
• MAPK inhibitors serve as valuable tools for studying melanoma biology in its microenvironment.